VisionPoint Advisory Group LLC Has $103,000 Stock Position in STERIS plc (NYSE:STE)

VisionPoint Advisory Group LLC increased its holdings in shares of STERIS plc (NYSE:STE) by 19.9% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 507 shares of the medical equipment provider’s stock after buying an additional 84 shares during the quarter. VisionPoint Advisory Group LLC’s holdings in STERIS were worth $103,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of STE. Ashton Thomas Securities LLC bought a new position in shares of STERIS in the third quarter worth about $25,000. Human Investing LLC acquired a new position in STERIS during the 4th quarter worth approximately $31,000. Central Pacific Bank Trust Division lifted its stake in STERIS by 65.5% in the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 76 shares during the last quarter. Manchester Capital Management LLC boosted its position in STERIS by 182.7% in the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider’s stock valued at $44,000 after buying an additional 137 shares in the last quarter. Finally, Quarry LP bought a new stake in shares of STERIS during the third quarter worth $67,000. 94.69% of the stock is owned by institutional investors and hedge funds.

Insider Activity at STERIS

In other STERIS news, SVP Cary L. Majors sold 1,682 shares of the stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $217.32, for a total transaction of $365,532.24. Following the completion of the sale, the senior vice president now directly owns 11,372 shares in the company, valued at approximately $2,471,363.04. This trade represents a 12.88 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 1.14% of the stock is owned by company insiders.

STERIS Trading Down 0.2 %

NYSE STE opened at $220.43 on Friday. The firm has a market capitalization of $21.66 billion, a PE ratio of 46.80 and a beta of 0.84. The business’s 50-day moving average price is $213.47 and its two-hundred day moving average price is $223.64. The company has a current ratio of 2.13, a quick ratio of 1.40 and a debt-to-equity ratio of 0.32. STERIS plc has a 12 month low of $197.82 and a 12 month high of $248.24.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 EPS for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. On average, analysts expect that STERIS plc will post 9.08 EPS for the current year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 21st. Investors of record on Thursday, February 20th will be paid a dividend of $0.57 per share. This represents a $2.28 dividend on an annualized basis and a yield of 1.03%. The ex-dividend date is Thursday, February 20th. STERIS’s dividend payout ratio is presently 48.41%.

Wall Street Analyst Weigh In

STE has been the subject of a number of research reports. Needham & Company LLC reiterated a “hold” rating on shares of STERIS in a research note on Friday, November 8th. Piper Sandler increased their target price on STERIS from $260.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday, February 3rd. Stephens reissued an “overweight” rating and set a $240.00 price target on shares of STERIS in a research note on Thursday, February 6th. JMP Securities reaffirmed a “market outperform” rating and issued a $265.00 price objective on shares of STERIS in a research note on Thursday, February 6th. Finally, StockNews.com downgraded shares of STERIS from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, October 29th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $258.75.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.